#USA #Boston #Field Medical #AF Symposium #PULSE Study

Field Medical Unveils Innovative Approaches in Cardiac Ablation at AF Symposium 2026

In a significant presentation at the AF Symposium 2026, ongoing from February 5 to 7 in Boston, Field Medical, Inc. unveiled the latest findings from the PULSE study. This clinical-stage medtech company, focusing on pulsed field ablation (PFA) technology, showcased the rapid advancements in managing complex cardiac arrhythmias. The study highlights the efficacy of their FieldForce™ Ablation System, designed to facilitate immediate ablation without prolonged contact between the catheter and tissue.

PULSE Study Overview

The PULSE study evaluated a novel high-voltage pulsed waveform that can deliver energy quickly, allowing for instantaneous lesion formations in less than 200 milliseconds. The system, which utilizes a focal, contact-sensitive catheter, demonstrated a mean procedure time for bilateral pulmonary vein isolation (PVI) of just 12.5 minutes, with some patients being treated in as few as 7.7 minutes. Such efficiency is crucial in the fast-paced dynamics of cardiac procedures, potentially improving patient outcomes significantly.

Dr. Vivek Y. Reddy, the lead investigator from Mount Sinai, emphasized that the technique preserves physician flexibility while maximizing the advantages of pulsed field technologies. "Our approach allows for tailored lesion sets while providing a previously unattainable level of procedural efficacy," he remarked during the findings presentation, which was part of the Late Breaking Clinical Trial session.

Key Findings

The data revealed compelling results:

• - Immediate Lesion Creation: Lesions formed in under 200 milliseconds, enabling rapid individual point ablation.
• - Efficiency: With an average procedure time of 12.5 minutes for PVI, this method promises a marked reduction in time spent in the operating room.
• - PVI Durability: The data showed an impressive increase in the durability of PVI with the new optimized waveform, boasting success rates of 94.2% and 84.6% respectively for different patient cohorts.

Moreover, the findings highlighted an absence of serious adverse events related to the device, with no reports of acute kidney injury or clinically significant hemolysis. MRI scans of participating patients exhibited no silent brain lesions, further underscoring the safety profile of the new technique.

Implications for Cardiac Treatment

Field Medical's advancements signal a transformative step in how arrhythmias, particularly atrial fibrillation (AF), can be efficiently managed. The ability to create lesions swiftly and effectively could lead to improved patient safety and better clinical outcomes, as evidenced by earlier published data on ventricular tachycardia treatment.

Dr. Steven Mickelsen, Founder and Chief Technology Officer of Field Medical, stated, "We are committed to developing focused PFA as a solution to the inherent limitations of existing techniques and validating its use through clinical data. Our method not only minimizes dependence on prolonged catheter stability but also harnesses rapid energy delivery to adapt dynamically to heart movements."

Educational Sessions at the Symposium

Continuing the discussion, Field Medical engaged attendees through numerous educational sessions scheduled during the symposium, including a presentation titled Maximizing Lesion Depth Using High Voltage PFA Waveform by Dr. Kenneth Ellenbogen. Another anticipated talk on the clinical applications of the FieldForce Ablation System was delivered by Dr. Reddy.

Field Medical's innovations with pulsed field ablation have the potential to reshape the standards of care for patients with complex arrhythmias. The technology emphasizes not only procedural efficiency but also enhanced patient safety—two critical factors in the future of cardiac healthcare. As the industry evolves, Field Medical is positioned to be at the forefront, driving the transition toward more effective and less invasive cardiac treatments.